General
Preferred name
WHI-P180
Synonyms
WHI-P180 (hydrochloride) ()
Janex 3 hydrochloride ()
WHIP180 ()
cmpd 2 ()
Janex 3 ()
4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline ()
WHI-P180 hydrochloride ()
P&D ID
PD007048
CAS
211555-08-7
153437-55-9
Tags
available
drug candidate
Drug indication
Discovery agent
Drug Status
experimental
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits RET, KDR and EGFR with IC50s of 5 nM, 66 nM and 4 ¦ÌM, respectively.
PRICE
97
DESCRIPTION
WHI-P180 (Janex 3) is a potent inhibitor of EGFR and Cdk2, with IC50 values of 4.0 ??M and 1.0 ??M, respectively.
DESCRIPTION
WHI-P180 (Janex 3) is a potent inhibitor of EGFR and Cdk2, with IC50 values of 4.0 µM and 1.0 µM, respectively.
(TargetMol Bioactive Compound Library)
DESCRIPTION
WHI-P180 moderately inhibited ABCG2 function, exhibiting weak phototoxicity.
The elimination half-life of WHI-P180 in CD-1 mice (BALB/ c mice) following i.v., i.p., or p.o. administration was less than 10 min. Systemic clearance of WHI-P180 was 6742 mL/h/kg in CD-I mice and 8188 mL/h/kg in BALB/c mice. Notably, WHI-P180, when administered in two consecutive nontoxic i.p. bolus doses of 25 mg/kg, inhibited IgE/antigen-induced vascular hyperpermeability in a well-characterized murine model of passive cutaneous anaphylaxis. (BOC Sciences Bioactive Compounds)
The elimination half-life of WHI-P180 in CD-1 mice (BALB/ c mice) following i.v., i.p., or p.o. administration was less than 10 min. Systemic clearance of WHI-P180 was 6742 mL/h/kg in CD-I mice and 8188 mL/h/kg in BALB/c mice. Notably, WHI-P180, when administered in two consecutive nontoxic i.p. bolus doses of 25 mg/kg, inhibited IgE/antigen-induced vascular hyperpermeability in a well-characterized murine model of passive cutaneous anaphylaxis. (BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
5
Organisms
0
Compound Sets
10
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
CDK inhibitor database (CDKiDB)
DrugBank
DrugMAP
EUbOPEN Chemogenomics Library
MedChem Express Bioactive Compound Library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
25
Molecular Weight
297.11
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
3
Aromatic Ring Count
3
cLogP
3.1
TPSA
76.5
Fraction CSP3
0.12
Chiral centers
0.0
Largest ring
6.0
QED
0.77
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
VEGFR
EGFR
RET
CDK2
c-RET,VEGFR
Pathway
Protein Tyrosine Kinase/RTK
JAK/STAT Signaling
Angiogenesis
Apoptosis
Cell Cycle/Checkpoint
Tyrosine Kinase/Adaptors
Recommended Cell Concentration
1 uM
Source data
